DLL3, which shows surface expression specific to tumor cells, is thus an attractive therapeutic target, and DLL3-targeted therapies are currently under clinical investigation, with promising antitumor activity demonstrated to date (19). This evidence concerns the gene DLL3 and neoplasm.